AstraZeneca gets EU approval for heart failure drug Forxiga

This article was originally published here

The EU approval of Forxiga was based on data from the international, multi-centre, parallel-group, randomised and double-blinded DAPA-HF phase III trial. AstraZeneca claims that Forxiga is the first

The post AstraZeneca gets EU approval for heart failure drug Forxiga appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply